Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model
The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatmen...
Gespeichert in:
Veröffentlicht in: | American journal of ophthalmology 1993-12, Vol.116 (6), p.700-707 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 707 |
---|---|
container_issue | 6 |
container_start_page | 700 |
container_title | American journal of ophthalmology |
container_volume | 116 |
creator | Helm, Craig J. Holland, Gary N. Lin, Robert Berlin, O. George W. Bruckner, David A. |
description | The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatments significantly reduced the number of organisms in treated eyes compared to untreated, control eyes (all P values < .001). No significant difference in treatment efficacy was found between the three treatment groups (all P values ≥ .48), although ciprofloxacin (3 mg/ml) was more effective than clarithromycin (20 mg/ml) after excluding outliers (P = .01). All treatments stabilized or reduced the size of stromal infiltrates after four days of therapy, whereas infiltrates continued to enlarge in untreated eyes. These results suggest that topical clarithromycin, topical ciprofloxacin, and combined amikacin and vancomycin may all be clinically useful for treating M. fortuitum keratitis. Both clarithromycin and ciprofloxacin were better tolerated than combined amikacin and vancomycin. This study supports the further development of clarithromycin, a new macrolide antibiotic, as a topical drug for treatment of M. fortuitum keratitis. |
doi_str_mv | 10.1016/S0002-9394(14)73469-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76082992</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002939414734695</els_id><sourcerecordid>76082992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-358c6e55a1987ffcd46380d6e45349486417538e6c0d6ab506c977bed22877ba3</originalsourceid><addsrcrecordid>eNqFkEtLxTAQhYMoen38BKEr0UU1afNciVx8oeLC6zqk6VQibXNNUsF_b-4Dt64mmXPmTPIhdErwJcGEX71hjKtS1YqeE3ohaspVyXbQjEihSiIV2UWzP8sBOozxM1-5oGIf7cuKYSyqGbJzPyxNcNGPhe-KhV86a_riZkyucT45G4vOh2IRwCQ3fhQvP9Y3xiYIbhpWUppcyqcnCNmQXCzcWJgxB7gh57z4FvpjtNeZPsLJth6h97vbxfyhfH69f5zfPJe25jiVNZOWA2OGKCm6zraU1xK3HCirqaKSUyJYLYHb3DQNw9wqIRpoq0rmauojdLbJXQb_NUFMenDRQt-bEfwUteBYVkpV2cg2Rht8jAE6vQz5ueFHE6xXcPUarl6R04TqNVzN8tzpdsHUDND-TW1pZv16o0P-5beDoKN1MFpoXQCbdOvdPxt-AUmiiac</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76082992</pqid></control><display><type>article</type><title>Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Helm, Craig J. ; Holland, Gary N. ; Lin, Robert ; Berlin, O. George W. ; Bruckner, David A.</creator><creatorcontrib>Helm, Craig J. ; Holland, Gary N. ; Lin, Robert ; Berlin, O. George W. ; Bruckner, David A.</creatorcontrib><description>The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatments significantly reduced the number of organisms in treated eyes compared to untreated, control eyes (all P values < .001). No significant difference in treatment efficacy was found between the three treatment groups (all P values ≥ .48), although ciprofloxacin (3 mg/ml) was more effective than clarithromycin (20 mg/ml) after excluding outliers (P = .01). All treatments stabilized or reduced the size of stromal infiltrates after four days of therapy, whereas infiltrates continued to enlarge in untreated eyes. These results suggest that topical clarithromycin, topical ciprofloxacin, and combined amikacin and vancomycin may all be clinically useful for treating M. fortuitum keratitis. Both clarithromycin and ciprofloxacin were better tolerated than combined amikacin and vancomycin. This study supports the further development of clarithromycin, a new macrolide antibiotic, as a topical drug for treatment of M. fortuitum keratitis.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/S0002-9394(14)73469-5</identifier><identifier>PMID: 8250072</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Topical ; Amikacin - therapeutic use ; Animals ; Ciprofloxacin - therapeutic use ; Clarithromycin - therapeutic use ; Colony Count, Microbial ; Corneal Stroma - microbiology ; Disease Models, Animal ; Drug Therapy, Combination - therapeutic use ; Eye Infections, Bacterial - drug therapy ; Keratitis - drug therapy ; Keratitis - microbiology ; Male ; Mycobacterium Infections, Nontuberculous - drug therapy ; Ophthalmic Solutions ; Rabbits ; Vancomycin - therapeutic use</subject><ispartof>American journal of ophthalmology, 1993-12, Vol.116 (6), p.700-707</ispartof><rights>1993 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-358c6e55a1987ffcd46380d6e45349486417538e6c0d6ab506c977bed22877ba3</citedby><cites>FETCH-LOGICAL-c360t-358c6e55a1987ffcd46380d6e45349486417538e6c0d6ab506c977bed22877ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9394(14)73469-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8250072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Helm, Craig J.</creatorcontrib><creatorcontrib>Holland, Gary N.</creatorcontrib><creatorcontrib>Lin, Robert</creatorcontrib><creatorcontrib>Berlin, O. George W.</creatorcontrib><creatorcontrib>Bruckner, David A.</creatorcontrib><title>Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatments significantly reduced the number of organisms in treated eyes compared to untreated, control eyes (all P values < .001). No significant difference in treatment efficacy was found between the three treatment groups (all P values ≥ .48), although ciprofloxacin (3 mg/ml) was more effective than clarithromycin (20 mg/ml) after excluding outliers (P = .01). All treatments stabilized or reduced the size of stromal infiltrates after four days of therapy, whereas infiltrates continued to enlarge in untreated eyes. These results suggest that topical clarithromycin, topical ciprofloxacin, and combined amikacin and vancomycin may all be clinically useful for treating M. fortuitum keratitis. Both clarithromycin and ciprofloxacin were better tolerated than combined amikacin and vancomycin. This study supports the further development of clarithromycin, a new macrolide antibiotic, as a topical drug for treatment of M. fortuitum keratitis.</description><subject>Administration, Topical</subject><subject>Amikacin - therapeutic use</subject><subject>Animals</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Clarithromycin - therapeutic use</subject><subject>Colony Count, Microbial</subject><subject>Corneal Stroma - microbiology</subject><subject>Disease Models, Animal</subject><subject>Drug Therapy, Combination - therapeutic use</subject><subject>Eye Infections, Bacterial - drug therapy</subject><subject>Keratitis - drug therapy</subject><subject>Keratitis - microbiology</subject><subject>Male</subject><subject>Mycobacterium Infections, Nontuberculous - drug therapy</subject><subject>Ophthalmic Solutions</subject><subject>Rabbits</subject><subject>Vancomycin - therapeutic use</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLxTAQhYMoen38BKEr0UU1afNciVx8oeLC6zqk6VQibXNNUsF_b-4Dt64mmXPmTPIhdErwJcGEX71hjKtS1YqeE3ohaspVyXbQjEihSiIV2UWzP8sBOozxM1-5oGIf7cuKYSyqGbJzPyxNcNGPhe-KhV86a_riZkyucT45G4vOh2IRwCQ3fhQvP9Y3xiYIbhpWUppcyqcnCNmQXCzcWJgxB7gh57z4FvpjtNeZPsLJth6h97vbxfyhfH69f5zfPJe25jiVNZOWA2OGKCm6zraU1xK3HCirqaKSUyJYLYHb3DQNw9wqIRpoq0rmauojdLbJXQb_NUFMenDRQt-bEfwUteBYVkpV2cg2Rht8jAE6vQz5ueFHE6xXcPUarl6R04TqNVzN8tzpdsHUDND-TW1pZv16o0P-5beDoKN1MFpoXQCbdOvdPxt-AUmiiac</recordid><startdate>19931215</startdate><enddate>19931215</enddate><creator>Helm, Craig J.</creator><creator>Holland, Gary N.</creator><creator>Lin, Robert</creator><creator>Berlin, O. George W.</creator><creator>Bruckner, David A.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19931215</creationdate><title>Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model</title><author>Helm, Craig J. ; Holland, Gary N. ; Lin, Robert ; Berlin, O. George W. ; Bruckner, David A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-358c6e55a1987ffcd46380d6e45349486417538e6c0d6ab506c977bed22877ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Administration, Topical</topic><topic>Amikacin - therapeutic use</topic><topic>Animals</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Clarithromycin - therapeutic use</topic><topic>Colony Count, Microbial</topic><topic>Corneal Stroma - microbiology</topic><topic>Disease Models, Animal</topic><topic>Drug Therapy, Combination - therapeutic use</topic><topic>Eye Infections, Bacterial - drug therapy</topic><topic>Keratitis - drug therapy</topic><topic>Keratitis - microbiology</topic><topic>Male</topic><topic>Mycobacterium Infections, Nontuberculous - drug therapy</topic><topic>Ophthalmic Solutions</topic><topic>Rabbits</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Helm, Craig J.</creatorcontrib><creatorcontrib>Holland, Gary N.</creatorcontrib><creatorcontrib>Lin, Robert</creatorcontrib><creatorcontrib>Berlin, O. George W.</creatorcontrib><creatorcontrib>Bruckner, David A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Helm, Craig J.</au><au>Holland, Gary N.</au><au>Lin, Robert</au><au>Berlin, O. George W.</au><au>Bruckner, David A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>1993-12-15</date><risdate>1993</risdate><volume>116</volume><issue>6</issue><spage>700</spage><epage>707</epage><pages>700-707</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><abstract>The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatments significantly reduced the number of organisms in treated eyes compared to untreated, control eyes (all P values < .001). No significant difference in treatment efficacy was found between the three treatment groups (all P values ≥ .48), although ciprofloxacin (3 mg/ml) was more effective than clarithromycin (20 mg/ml) after excluding outliers (P = .01). All treatments stabilized or reduced the size of stromal infiltrates after four days of therapy, whereas infiltrates continued to enlarge in untreated eyes. These results suggest that topical clarithromycin, topical ciprofloxacin, and combined amikacin and vancomycin may all be clinically useful for treating M. fortuitum keratitis. Both clarithromycin and ciprofloxacin were better tolerated than combined amikacin and vancomycin. This study supports the further development of clarithromycin, a new macrolide antibiotic, as a topical drug for treatment of M. fortuitum keratitis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>8250072</pmid><doi>10.1016/S0002-9394(14)73469-5</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9394 |
ispartof | American journal of ophthalmology, 1993-12, Vol.116 (6), p.700-707 |
issn | 0002-9394 1879-1891 |
language | eng |
recordid | cdi_proquest_miscellaneous_76082992 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Administration, Topical Amikacin - therapeutic use Animals Ciprofloxacin - therapeutic use Clarithromycin - therapeutic use Colony Count, Microbial Corneal Stroma - microbiology Disease Models, Animal Drug Therapy, Combination - therapeutic use Eye Infections, Bacterial - drug therapy Keratitis - drug therapy Keratitis - microbiology Male Mycobacterium Infections, Nontuberculous - drug therapy Ophthalmic Solutions Rabbits Vancomycin - therapeutic use |
title | Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T08%3A39%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Topical%20Antibiotics%20for%20Treating%20Mycobacterium%20fortuitum%20Keratitis%20in%20an%20Animal%20Model&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Helm,%20Craig%20J.&rft.date=1993-12-15&rft.volume=116&rft.issue=6&rft.spage=700&rft.epage=707&rft.pages=700-707&rft.issn=0002-9394&rft.eissn=1879-1891&rft_id=info:doi/10.1016/S0002-9394(14)73469-5&rft_dat=%3Cproquest_cross%3E76082992%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76082992&rft_id=info:pmid/8250072&rft_els_id=S0002939414734695&rfr_iscdi=true |